FindTrial
Sign In

Prospective control study of adjuvant TACE combined with rivarotinib and TACE alone after hepatectomy for multiple hepatocellular carcinoma

Prospective and open clinical study of adjuvant TACE combined with rivarotinib and TACE alone after hepatectomy for multiple hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036612
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-10
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple heopatocellular carcinomas

Interventions

Experimental group:TACE combined with Rivatinib
Control group:TACE alone

Sponsors

Third Affiliated Hospital of the Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The age is 20-70 years old, male or female; 2. Preoperative PS score was 0-1; 3. Preoperative liver function was Child A; 4. There was no extrahepatic organ and tissue metastasis; 5. There was no invasion of main portal vein and its main branches, no tumor thrombus in main hepatic vein and biliary tract.

Exclusion criteria

Exclusion criteria: 1. Anti tumor therapy was performed before operation; 2. Palliative treatment was given to the tumor; 3. History of other malignant tumors; 4. Severe complications occurred within 1 month after operation; 5. Patients who did not receive anti recurrence treatment as required after operation.

Design outcomes

Primary

MeasureTime frame
Overall survival;Time to recurrence;—

Countries

China

Contacts

Public ContactYang pinghua

The Third Affiliated Hospital of the Second Military Medical University

yangpinghua2008@163.com+86 15800332872

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026